Abstract
Thymogen effect was assessed in patients with type 1 diabetes mellitus with clinical and laboratory evidence of secondary immunodeficiency. It was found that thymogen removes signs of secondary immunodeficiency due to activation of T-lymphocyte differentiation. Clinical effect of thymogen was registered in 94.4%, laboratory effect in 83.3% of patients. The scheme of thymogen administration is suggested.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Adjuvants, Immunologic / administration & dosage*
-
Adolescent
-
Adult
-
Autoimmune Diseases / blood
-
Autoimmune Diseases / drug therapy*
-
Autoimmune Diseases / immunology
-
Child
-
Chronic Disease
-
Diabetes Mellitus, Type 1 / blood
-
Diabetes Mellitus, Type 1 / drug therapy*
-
Diabetes Mellitus, Type 1 / immunology
-
Dipeptides*
-
Drug Evaluation
-
Humans
-
Immunity, Cellular / drug effects
-
Peptides / administration & dosage*
-
Time Factors
Substances
-
Adjuvants, Immunologic
-
Dipeptides
-
Peptides
-
thymogen